Helena Yu, MD
Internal Medicine · New York, NYNPI 1871791665
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $161,822 of the $198,392 with a category attached, or 81.6%. It is spread thinly across 21 manufacturers, the largest accounting for just 19.4%. Among internal medicine clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 151 payments — averaging $1313.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$39K
- Takeda Pharmaceuticals U.S.A., Inc.$27K
- Daiichi Sankyo Inc.$19K
- Astrazeneca UK Limited$18K
- Johnson & Johnson$18K
- Janssen Scientific Affairs, LLC$16K
- plus $61K from 15 others
Across 814 payments — averaging $62,291 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$33.8M
- Pfizer$10.1M
- Daiichi Sankyo Inc.$4.6M
- Janssen Research & Development, LLC$1M
- Novartis$628K
- Blueprint Medicines Corporation$190K
- plus $389K from 4 others
What the payments were for
- Consulting fees$161,82282%
- Speaking & faculty fees$19,63310%
- Travel & lodging$14,8527%
- Food & beverage$2,0851%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 30 | $38,550 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $26,892 |
| Daiichi Sankyo Inc. | 18 | $19,453 |
| Astrazeneca UK Limited | 20 | $18,459 |
| Johnson & Johnson(2 entities) | 16 | $18,174 |
| Janssen Scientific Affairs, LLC | 14 | $15,848 |
| Janssen Global Services, LLC | 11 | $11,060 |
| Merck | 8 | $7,687 |
| Gilead | 2 | $7,150 |
| AbbVie | 2 | $5,738 |
| Novocure Inc. | 2 | $5,099 |
| Blueprint Medicines Corporation | 3 | $4,788 |
| E.r. Squibb & Sons, L.L.C. | 4 | $4,371 |
| Ipsen Bioscience Inc. | 1 | $4,350 |
| Taiho Oncology, Inc. | 2 | $2,196 |
| Bayer | 1 | $2,100 |
| Rigel Pharmaceuticals, Inc. | 3 | $1,870 |
| Array Biopharma Inc | 2 | $1,541 |
| Orion Corporation | 2 | $1,511 |
| Puma Biotechnology, Inc. | 1 | $908 |
| Boehringer Ingelheim | 1 | $650 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$198,392 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 241 | $4,106,159 |
| TepmetkoTepotinib Hcl | 25 | $460,403 |
| Erlotinib Hcl | 35 | $78,836 |
| XareltoRivaroxaban | 33 | $22,251 |
| EliquisApixaban | 17 | $9,662 |
| Fentanyl | 13 | $1,786 |
| Dexamethasone | 51 | $1,043 |
| Mirtazapine | 37 | $321 |
| Pantoprazole Sodium | 33 | $281 |
| Ondansetron OdtOndansetron | 27 | $224 |
| Olanzapine | 20 | $149 |
| Escitalopram Oxalate | 16 | $140 |
| Prednisone | 22 | $114 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 14 | $34 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso | $38,550 | $4,106,159241 claims |
| Johnson & JohnsonXarelto | $18,174 | $22,25133 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in New York
- Stephen SaletanNew York$2.6M
- Ziad AliNew York$2M
- Ricky HsuNew York$1M
- James UnderbergNew York$953K
- Terry PlasseNew York$883K
- Krisczar BungayNew York$554K
- Eytan SteinNew York$496K
- Larry NeumanNew York$457K
- Wuhua JingNew York$338K
- Harvey SchneienNew York$334K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.